Altimmune Stock

Altimmune Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Altimmune (ALT) as of Aug 5, 2026 is 76.66 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 84.00 % — a change of -8.73% (lower).

Cash Conversion

76.66 %

YoY

-8.73%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Altimmune is 2026 76.66 % . Cash Conversion Rate (OCF/Net Income) of Altimmune was 2025 84.00 % . It decreases by -8.73% lower compared to the previous year.
Access this data via the Eulerpool API

Altimmune Stock analysis

What does Altimmune do? Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Altimmune stock

Cash Conversion Rate (OCF/Net Income) of Altimmune is 76.66 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Altimmune changed from 84.00 % to 76.66 %, representing a -8.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Altimmune since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Altimmune with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Altimmune

All Key Metrics — Altimmune